Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Pfizer net profit...

    Pfizer net profit rises 52 percent in July-September

    Written by supriya kashyap kashyap Published On 2016-11-09T11:37:08+05:30  |  Updated On 9 Nov 2016 11:37 AM IST
    Pfizer net profit rises 52 percent in July-September

    Kolkata : Pharmaceuticals major Pfizer Limited reported a 52 per cent rise in its net profit to Rs 126 crore in the three months ended on September 30, 2016 as compared to Rs 83 crore in the corresponding period last year.


    Revenues for the quarter were at Rs 552 crore, up 5 per cent, from Rs 525 crore in the year-ago period.


    "This quarter witnessed the full impact of the price reductions announced by the Government between March and June of this year. Revenue has been impacted by Rs 22 crore due to these price reductions with the impact being felt most in mid-tier and tail brands," the company said in a statement.


    The company further said that excluding the impact of price reductions, revenue growth for the quarter would have been 9 per cent.


    Profit from operations (before other income, exceptional items and tax) for the quarter and half of the current fiscal year (April-September) was primarily impacted by "pricing policy".


    During the quarter under review, the company on completion of requisite formalities and receipt of necessary regulatory approvals concluded the transfer of four brands for a consideration of Rs 110 crore, the statement added.


    Revenue for the half year stood at Rs 1,066 crore as compared to Rs 1,022 crore in the same period last year, reflecting a growth of 4 per cent.


    Net profit after tax (including other comprehensive income) for the first six months was at Rs 206 crore, up by 31 per cent, as against Rs 158 crore in the same period last year.

    July-Septembernet profit rises 52%Pfizerpricing policy
    Source : IANS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok